The Center for the Study of Inflammatory Bowel Disease (CSIBD) is a multidisciplinary program to define fundamental mechanisms underlying Crohn's disease and Ulcerative colitis. This Center encompasses one hundred and one investigators at the Massachusetts General Hospital (MGH) and allied institutions pursuing research in a broad spectrum of basic science relevant to IBD. Since its formation nineteen years ago, the CSIBD has served as a vehicle to achieve advances in our understanding of these diseases through the study of relevant basic biological processes and the directed study of the diseases themselves. The research program of this Center is organized around the central hypothesis that IBD results from activation by luminal bacteria or their products of an upregulated chronic immune response due to genetically determined alterations of epithelial cell or immune function including a lack of appropriate down regulatory functions. Major advances made possible by the CSIBD in the years since its inception include the development and characterization of new genetic mouse models of IBD, delineation of mechanisms of lymphocyte activation and leukocyte recruitment to sites of inflammation, characterization of mechanisms of innate immune response, identification of key peptides involved in sustaining mucosal integrity, characterization of the mechanisms of mucosal healing following injury, improved understanding of the regulation of epithelial function, functional mapping of genetic variants in IBD, mucosal immune responses and delineation of the mechanisms of mucosal microbial interaction. Over the next five years, the CSIBD will promote further progress in the study of basic aspects of mucosal biology with translation to the study and treatment of IBD. A major focus of CSIBD research in the next five years will be the coordinated multi-disciplinary study of mechanisms leading to chronic intestinal inflammation and delineation of interactions between environmental factors and different genetic loci. The Center will also actively promote clinical and translational research efforts to apply insights gained in studying various disease mechanisms. The overall goal of advancing our knowledge of IBD will continue to be carried out through five Biomedical Cores. These include Genetic analysis, Genomics and Molecular Biology (GGMB), Morphology and Immunology Cores to provide access to advanced technologies. The Genetic Animal Models and Human Cell/Tissue Cores provide access to relevant animal models and patients for study. In the coming period facilitated access for CSIBD investigators to several platforms of the Broad institute has been arranged. CSIBD cores are heavily oriented towards hands on training. In addition to advancing the understanding of IBD per se, the goals of this Center will continue to include the recruitment of investigators committed to pursuing IBD research. These goals are fostered by Pilot/Feasibility Study awards which support new research initiatives as well as an enrichment program of seminars, workshops and symposia.

Public Health Relevance

The center provides high quality, cutting edge and technical support to investigators performing inflammatory bowel disease related research. It also provides pilot feasibility grants for IBD related research, a resource that has been avidly sought by area investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK043351-22
Application #
8220720
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (M1))
Program Officer
Podskalny, Judith M,
Project Start
1997-01-01
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
22
Fiscal Year
2012
Total Cost
$1,327,806
Indirect Cost
$515,868
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Yassour, Moran; Vatanen, Tommi; Siljander, Heli et al. (2016) Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med 8:343ra81
Kassam, Z; Cribb Fabersunne, C; Smith, M B et al. (2016) Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther 43:725-33
Wang, Ninghai; Keszei, Marton; Halibozek, Peter et al. (2016) Slamf6 negatively regulates autoimmunity. Clin Immunol 173:19-26
Rivas, Manuel A; Graham, Daniel; Sulem, Patrick et al. (2016) Erratum: A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun 7:12869
Sundberg, Thomas B; Liang, Yanke; Wu, Huixian et al. (2016) Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo. ACS Chem Biol 11:2105-11
Li, Dalin; Achkar, Jean-Paul; Haritunians, Talin et al. (2016) A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology 151:724-32
Salloum, Shadi; Holmes, Jacinta A; Jindal, Rohit et al. (2016) Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types. Hepatology 64:1951-1968
Breton, Sylvie; Ruan, Ye Chun; Park, Yoo-Jin et al. (2016) Regulation of epithelial function, differentiation, and remodeling in the epididymis. Asian J Androl 18:3-9
O'Connell, Daniel J; Kolde, Raivo; Sooknah, Matthew et al. (2016) Simultaneous Pathway Activity Inference and Gene Expression Analysis Using RNA Sequencing. Cell Syst 2:323-34
Cheung, Pui W; Nomura, Naohiro; Nair, Anil V et al. (2016) EGF Receptor Inhibition by Erlotinib Increases Aquaporin 2-Mediated Renal Water Reabsorption. J Am Soc Nephrol 27:3105-3116

Showing the most recent 10 out of 901 publications